UMSOM-Led Clinical Trial Using Focused Ultrasound with Chemotherapy Finds Potential Survival Benefit for Brain Cancer Patients
UMSOM-Led Clinical Trial Using Focused Ultrasound with Chemotherapy Finds Potential Survival Benefit for Brain Cancer Patients
Patients with the deadliest form of brain cancer, glioblastoma, who received MRI-guided focused ultrasound with standard-of-care chemotherapy had a nearly 40 percent increase in overall survival in a landmark trial of 34 patients led by Íøºì±¬ÁÏ School of Medicine (UMSOM) researchers. This is the first time researchers have demonstrated a potential survival benefit from using focused ultrasound to open the blood-brain barrier to improve delivery of chemotherapy to the tumor site in brain cancer patients after surgery.
Learn more about for the future of brain cancer treatment and monitoring.
Photo: Graeme Woodworth, MD, professor and chair of neurosurgery at UMSOM and neurosurgeon-in-chief at the Íøºì±¬ÁÏ Medical Center, is principal investigator of the study.